Eli Lilly and Company

LLY

US5324571083

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Employees

43,000

Sector

Pharmaceuticals

Calendar

2024-10-30 - Q3 2024 Earnings Release

More about the company

Income Statement and Estimates

More financial data

Analysis / Opinion

David Ricks, CEO of Eli Lilly: A market of over a billion people

March 12, 2024 at 02:47 pm EDT

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

923.71USD

Average target price

995.42USD

Spread / Average Target

+7.76%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 04:00:02 2024-09-13 pm EDT			After market 06:46:12 pm
923.71 ^USD	-1.21%		927.50	+0.41%

Sep. 13	Eli Lilly Gets FDA Approval for Eczema Treatment Ebglyss	DJ
Sep. 13	Eli Lilly Gets US FDA Approval for Atopic Dermatitis Treatment	MT

Eli Lilly Gets FDA Approval for Eczema Treatment Ebglyss	Sep. 13	DJ
Eli Lilly Gets US FDA Approval for Atopic Dermatitis Treatment	Sep. 13	MT
Correction to Eli Lilly Gets FDA Approval for Eczema Treatment Article	Sep. 13	DJ
A central bank and it's off again?	Sep. 13
JPMorgan Raises Price Target on Eli Lilly to $1,100 From $1,050	Sep. 13	MT
Eli Lilly to Expand Two Ireland Sites With $1.8 Billion Investment	Sep. 12	MT
Eli Lilly invests $1.8 billion in Ireland sites to scale up Alzheimer's, obesity drug production	Sep. 12	RE
Sector Update: Health Care Stocks Rise in Thursday Trading	Sep. 12	MT
Sector Update: Health Care	Sep. 12	MT
Top Midday Stories: Moderna Shares Tumble on R&D Expense Cuts; Mastercard to Buy Recorded Future for $2.65 Billion	Sep. 12	MT
Eli Lilly Investing Additional $1 Billion in Ireland Manufacturing Plant	Sep. 12	DJ
ECB to cut rates without lowering its guard	Sep. 12
Eli Lilly: invests $1.8 billion in two sites in Ireland	Sep. 12	CF
Eli Lilly Invests $1.8 Billion in Ireland Site Expansions	Sep. 12	MT
Roche shares drop on side effects result in early-stage obesity pill trial	Sep. 12	RE
Eli Lilly: phase 3 trials on weekly insulin	Sep. 11	CF
Health Care Up on Defensive Bias -- Health Care Roundup	Sep. 10	DJ
Weight-loss market to see 16 new drugs by 2029, report estimates	Sep. 10	RE
Eli Lilly Says Efsitora Effective in Adults With Type 1 or 2 Diabetes in Phase 3 Trials	Sep. 10	MT
Nanosyrinx Ltd. announced that it has received £10 million in funding from BGF Investment Management Ltd., Merck Ventures B.V., Octopus Ventures Ltd., Eli Lilly and Company, IQ Capital Partners LLP, Meltwind Advisory	Sep. 09	CI
Lilly appoints insider as finance chief amid rising investments to boost capacity	Sep. 09	RE
The market burns its idols	Sep. 09
Eli Lilly Appoints New Finance Chief	Sep. 09	MT
Eli Lilly: in-house executive appointed CFO	Sep. 09	CF
Eli Lilly Appoints Lucas Montarce CFO	Sep. 09	MT

Eli Lilly and Company

Equities

LLY